Skip to content
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Home
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
      • Terms of Use
      • FCOI
      • Privacy Policy
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive

Posts in: perriman

Q&A: Tyler Korman, Michael Heltzen, Damien Perriman
heltzeninvestorvideoperrimankorman
Transcript: Q2 2026 investor update from EXOZAugust 21, 2026
NCT process advances beyond original commercial-scale economic targets
press releaseinvestorscienceperrimanNCT
eXoZymes' NCT process achieves 10-fold productivity increase, advancing beyond original commercial-scale economic targetsAugust 18, 2026
Webull 'Biotech Sector' webinar by Perriman
investorpress clippingsvideopodcastperriman
Webull: 'Biotech Sector' webinar by Damien PerrimanJune 30, 2026
Ladder17 podcast: How eXoZymes is Scaling as a Public Company
nutraceuticalspress clippingspodcastperrimanNCT
Ladder17 podcast: How eXoZymes is Scaling as a Public CompanyJune 25, 2026
Webull Biotech Sector Webinar
investorperriman
CCO of eXoZymes, Perriman, to present at Webull's 'Biotech Sector' webinarJune 18, 2026
Damien Perriman interviewed for Springwise
press clippingsperrimanNCT
Springwise case study: Unpacking how eXoZymes and Cayman Chemical are rethinking chemical manufacturingApril 17, 2026
Grow Everything podcast featuring Damien Perriman
press releasenutraceuticalsmedicinepress clippingsvideosciencepodcastperrimanNCT
eXoZymes CCO, Damien Perriman, outlines NCTx strategy and the commercial path for cell-free biomanufacturing on Grow Everything podcastApril 10, 2026
Perriman at Nasdaq
investornutraceuticalsmedicinepress clippingsvideoperrimanNCT
Nasdaq: Damien Perriman interview on NCTApril 2, 2026
eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade output
investornutraceuticalsmedicineperrimanNCT
EXOZ investor update: eXoZymes de-risks scale-up with Cayman Chemical, validating tech transfer with pharma-grade outputMarch 18, 2026
Video interview: Cayman Chemical validates eXoZymes' technology and scalability
press releasenutraceuticalsmedicinevideoperrimanNCT
Video interview: Successful pilot scale run with Cayman Chemical validates eXoZymes' technology and scalabilityMarch 18, 2026
Previous page
Page 1 of 2
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark